Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Alivexis","sponsor":"SBI Investments","pharmaFlowCategory":"D","amount":"$25.5 million","upfrontCash":"Undisclosed","newsHeadline":"Modulus Discovery Closes $25.5M USD Series B","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Alivexis","sponsor":"Green Coinvest Investment Limited","pharmaFlowCategory":"D","amount":"$20.4 million","upfrontCash":"Undisclosed","newsHeadline":"Modulus Discovery Closes $20.4M USD Series C","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery"},{"orgOrder":0,"company":"Alivexis","sponsor":"Melodia Therapeutics","pharmaFlowCategory":"D","amount":"$275.0 million","upfrontCash":"Undisclosed","newsHeadline":"Melodia and Alivexis Sign Exclusive License for Cathepsin C Inhibitor","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Alivexis

    Menu

    Alivexis

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Alivexis

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Melodia and Alivexis Sign Exclusive License for Cathepsin C Inhibitor

              Details:

              Under the terms of the agreement, Alivexis grants Melodia worldwide rights to develop, manufacture, and commercialize MDI-0151 for the treatment of inflammatory diseases.

              Lead Product(s): MDI-0151

              Therapeutic Area: Immunology Product Name: MDI-0151

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Melodia Therapeutics

              Deal Size: $275.0 million Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement June 21, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Alivexis

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Modulus Discovery Closes $20.4M USD Series C

              Details:

              Modulus will use the proceeds to further its portfolio of R&D programs driven by its proprietary computational drug discovery platform and globally networked operational model including lead asset MOD-A.

              Lead Product(s): MOD-A

              Therapeutic Area: Immunology Product Name: MOD-A

              Highest Development Status: Discovery Product Type: Small molecule

              Partner/Sponsor/Collaborator: Green Coinvest Investment Limited

              Deal Size: $20.4 million Upfront Cash: Undisclosed

              Deal Type: Series C Financing March 01, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Alivexis

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Modulus Discovery Closes $25.5M USD Series B

              Details:

              Modulus will use the proceeds to further its unique small-molecule lead programs in oncology and inflammatory / immune disorders and expand its portfolio of early programs and collaborations including those with its strategic partner, PeptiDream, Inc.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: SBI Investments

              Deal Size: $25.5 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing May 13, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY